Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.56 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.50 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317605 | 0.81 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL28210442 | 0.79 | AHR (0.54) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL5850255 | 0.75 | NPC1 (0.79) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL2530865 | 0.73 | GPR84 (0.67) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL228554 | 0.71 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL130519 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL131550 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL6017338 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL405311 | 0.71 | AHR (1.00) | AHRNR4A2CYP2A6F7LTA4H | |
| SCHEMBL130518 | 0.71 | AHR (0.56) | AHRNR4A2CYP2A6F7LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239883-A | Preparation method of lysine-specific demethylase 1 (LSD 1) inhibitor | 江苏联环药业股份有限公司 | 2024-06-25 | — | — | CN | claimed |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | claimed |
| EP-2593425-B1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | AGIOS PHARMACEUTICALS INC (US) | 2018-10-17 | — | — | EP | claimed |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2016-09-15 | — | — | US | claimed |
| CN-101495464-B | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2014-03-05 | — | — | CN | claimed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | claimed |
| CN-103396398-A | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA NV | 2013-11-20 | — | — | CN | claimed |
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC (US) | 2013-07-18 | — | — | US | claimed |
| EP-2593425-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHOD OF USE | Agios Pharmaceuticals, Inc. (US) | 2013-05-22 | — | — | EP | claimed |
| CN-103097340-A | Therapeutically active compositions and methods of use thereof | AGIOS PHARMACEUTICALS INC | 2013-05-08 | — | — | CN | claimed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | claimed |
| EP-1976528-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-08 | — | — | EP | claimed |
| EP-1973886-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | Janssen Pharmaceutica, N.V. (BE) | 2008-10-01 | — | — | EP | claimed |
| CN-100340632-C | Method for roughening copper surfaces for bonding to substrates | ELECTROCHEMICALS INC (US) | 2007-10-03 | — | — | CN | claimed |
| WO-2007107352-A1 | AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2007-09-27 | — | — | WO | claimed |
| WO-2007079214-A2 | PROKINETICIN 2 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| WO-2007079163-A2 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-12 | — | — | WO | claimed |
| CN-1653050-A | Opioid and opioid-like compounds and uses thereof | JENKEN BIOSCIENCES INC (US) | 2005-08-10 | — | — | CN | claimed |
| WO-2004004730-A2 | 2-AMINOPYRAZINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASES FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTEX TECHNOLOGY LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| CN-1451031-A | Method for roughening copper surfaces for bonding to substrates | ELECTROCHEMICALS INC (US) | 2003-10-22 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184222-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | AHR 1571/4885NR4A2 3294/4885CYP2A6 3816/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | AHR 3334/4885NR4A2 2308/4885CYP2A6 3896/4885 |
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | AHR 1267/4885NR4A2 407/4885CYP2A6 597/4885 |
| US-20160264621-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | IDH1, IDH3B, IDH3A | AHR 1571/4885NR4A2 3294/4885CYP2A6 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.